The latest update is out from Schroder UK Public Private Trust ( (GB:INOV) ).
Schroders Capital Global Innovation Trust announced the sale of its portfolio company, Araris Biotech, to Taiho Pharmaceutical for $400 million upfront, with potential milestone payments up to $740 million. This transaction is expected to significantly enhance the company’s net asset value and increase the initial return of capital to shareholders. The sale underscores Schroders Capital’s successful investment strategy and its ability to identify and nurture high-potential biotech firms, as evidenced by its strong realized track record of investments.
More about Schroder UK Public Private Trust
Schroders Capital Global Innovation Trust Plc is an investment company focused on innovative and high-growth sectors, particularly in biotechnology. It invests in companies developing cutting-edge technologies and solutions, with a strong emphasis on early-stage investments and strategic exits to maximize returns.
Technical Sentiment Consensus Rating: Buy
Find detailed analytics on INOV stock on TipRanks’ Stock Analysis page.